Nepexto (Etanercept)

Etanercept, the active ingredient in Nepexto, is a TNF-alpha inhibitor presented as a solution for subcutaneous injection for subcutaneous use. It treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and juvenile idiopathic arthritis.

GNH USA supplies Nepexto as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nepexto is a biologic disease-modifying antirheumatic drug that targets the TNF‑alpha pathway in inflammatory arthritis and related disorders.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriatic arthritis: improves skin lesions and joint symptoms. - Ankylosing spondylitis: alleviates spinal inflammation and enhances mobility. - Plaque psoriasis: decreases plaque formation and severity. - Juvenile idiopathic arthritis: controls disease activity in children.

Nepexto may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Upper respiratory infections: mild sinusitis or bronchitis. - Headache: transient, mild to moderate intensity. - Nausea: occasional gastrointestinal discomfort. - Rash: skin erythema or pruritus. - Fever: low‑grade temperature elevations.

Serious or Rare Side Effects: - Serious infections: tuberculosis, sepsis, or opportunistic infections. - Malignancies: increased risk of lymphoma or other cancers. - Demyelinating disease: new or worsening neurologic symptoms. - Heart failure exacerbation: worsening of pre‑existing cardiac insufficiency. - Lupus‑like syndrome: development of auto‑immune features. - Cytopenias: significant reductions in blood cell counts.

Before initiating Nepexto, several safety considerations should be reviewed.

- Screen for active infections: perform clinical assessment and appropriate laboratory tests. - Monitor for signs of infection: advise patients to report fever, cough, or unusual symptoms promptly. - Evaluate for tuberculosis: conduct TB screening prior to therapy. - Assess cardiac status: avoid use in uncontrolled heart failure. - Avoid live vaccines: contraindicated while receiving Etanercept. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nepexto can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: increased risk of infection due to immunosuppression. - Concurrent biologic DMARDs: additive immunosuppression heightens infection risk. - High‑dose systemic steroids: synergistic immunosuppressive effect.

Moderate Interactions (Monitor Closely): - Methotrexate: may increase hepatic toxicity. - Azathioprine: additive immunosuppression warrants monitoring. - Cyclosporine: combined use can raise infection susceptibility.